X4 Pharmaceuticals (XFOR) EBT Growth (1y) (2018 - 2026)
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) EBT Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 3.94% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 175.29% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -113.66% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -5.78% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -121.45% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -15.76% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 213.87% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 34.68% |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | 37.15% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 37.15% |
| Mar 31, 2026 | -6,505.38% |
| Dec 31, 2025 | 39.53% |
| Sep 30, 2025 | 18.64% |
| Jun 30, 2025 | -128.29% |
| Mar 31, 2025 | 100.61% |
| Dec 31, 2024 | -107.17% |
| Sep 30, 2024 | -1,509.52% |
| Jun 30, 2024 | 263.12% |
| Mar 31, 2024 | -115.47% |
| Dec 31, 2023 | 34.35% |
| Sep 30, 2023 | 89.45% |
| Jun 30, 2023 | -162.62% |
| Mar 31, 2023 | -9.45% |
| Dec 31, 2022 | 3.69% |
| Sep 30, 2022 | -7.07% |
| Jun 30, 2022 | -8.03% |
| Mar 31, 2022 | -17.53% |
| Dec 31, 2021 | -64.15% |
| Sep 30, 2021 | -15.61% |